Clinical Trials
3 trialsNCT06900595 2026-05-22
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07470489 2026-04-16
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07085572 2025-10-06
INTERVAL
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Recruiting